News / December 8, 2017

Nicotinamide Riboside Shown to Improve Mitochondrial Energy Production, Memory in Alzheimer's Disease

ChromaDex Corp. (NASDAQ:CDXC), a science-based, fully integrated nutraceutical company devoted to extending human healthspan, announced today that in research published in the journal Nature, Dr. Johan Auwerx showed that Alzheimer’s disease (AD) mice treated with nicotinamide riboside (NR) had lower levels of amyloid deposits, improved mitochondrial energy production and improved memory.

News / December 7, 2017

New Managing Director of Epax Norway AS

Pelagia, the parent company of Epax Norway AS, is pleased to announce that Bjørn Refsum is entering the position of Managing Director of Epax Norway AS as of January 1, 2018.